Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
2004 · British Journal of Cancer · 177 citations
https://doi.org/10.1038/sj.bjc.6602256
R
Russell Burcombe
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
106
Papers
1.2K
Citations
14
h-index
14
i10-index
Russell Burcombe is an academic researcher from Maidstone and Tunbridge Wells NHS Trust. The author has contributed to research in topics: Advanced Breast Cancer Therapies & PARP inhibition in cancer therapy & Breast Cancer Treatment Studies. The author has an h-index of 14, co-authored 91 publications.
ORCID: 0000-0001-5397-1132Papers by this author
worksEvaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
2006 · Breast Cancer Research · 85 citations
https://doi.org/10.1186/bcr1508
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
2022 · EBioMedicine · 25 citations
https://doi.org/10.1016/j.ebiom.2022.104205
Current treatment of HER 2+ metastatic breast cancer
2017 · British Journal of Nursing · 1 citations
https://doi.org/10.12968/bjon.2017.26.sup16a.s7
Implementation of Oncotype Dx to Guide Chemotherapy Sparing for Women with Postmenopausal N1-3, ER-positive, HER-2-negative Breast Cancer
2024 · Clinical Oncology · 1 citations
https://doi.org/10.1016/j.clon.2024.01.032
Oral Presentations 8
2004 · British Journal of Cancer · 0 citations
https://doi.org/10.1038/sj.bjc.6601933
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat